Treatments & Interventions
Chlorzoxazone
substance
Cyclobenzaprine hydrochloride
substance
Chlorphenesin carbamate
substance
Metaxalone
substance
Tizanidine hydrochloride
substance
Orphenadrine
substance
Tizanidine
substance
Chlorphenesin
substance
Cyclobenzaprine
substance
Carisoprodol
substance
Orphenadrine citrate
substance
Methocarbamol
substance
Orphenadrine hydrochloride
substance
Signs & Symptoms
Based on Human Phenotype Ontology (HPO) disease-phenotype annotations.
Muscle inflammation
HP:0100614
Proximal limb muscle weakness
HP:0003701
Related Conditions
Proliferative myositis(child)
Localised nodular myositis(child)
Maxillary myositis(child)
Infective myositis(child)
Polymyositis(child)
Interstitial myositis(child)
Inclusion body myositis(child)
Orbital myositis(child)
Lingual myositis(child)
Masticatory myositis(child)
Myositis in sarcoidosis(child)
Eosinophilic myositis(child)
Fibromyositis(child)
Talc granuloma of muscle(child)
Diaphragmitis(child)
Benign acute myositis(child)
Paraneoplastic myositis(child)
Autoimmune inflammation of skeletal muscle(child)
Dermatomyositis(child)
Idiopathic inflammatory myopathy(child)
Quick Facts
- SNOMED CT
- 26889001
- UMLS CUI
- C0027121
- Fully Specified Name
- Myositis (disorder)
- Specialists
- 0
- Diagnostic Biomarkers
- 0
- HPO Phenotypes
- 2
- Known Treatments
- 13
Medical Disclaimer
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Clinical content is derived from the SNOMED CT clinical ontology and curated medical knowledge graphs.